Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CLR457||Preclinical - Pdx||Actionable||In a preclinical study, CLR457 treatment of a variety of solid tumor patient-derived xenograft models decreased tumor volume and produced a 54% response (PMID: 26479923).||26479923|
|Unknown unknown||Advanced Solid Tumor||not applicable||CLR457||Phase I||Actionable||In a Phase I trial, CLR457 treatment demonstrated limited efficacy, resulting in no confirmed responses, stable disease in 25.8% (8/31) , and non-complete response/non-progressive disease in 6.5% (2/31) of patients with advanced solid tumors with PI3K pathway activation (PMID: 30073466; NCT02189174).||30073466|
|PubMed Id||Reference Title||Details|
|(26479923)||High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.||Full reference...|
|(30073466)||Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.||Full reference...|